Michal Sarfaty et al. showed clinical features of 14 lung cancer patients with RET fusions, whose median overall survival was 22.8 months, in which, that of the patients whose tumor harbor KIF5B–RET subtype was 13.3 months, compared with 22.8 months for CCDC6–RET subtype4. This evidence concerns the gene RET and neoplasm.